Astellas Venture Management

Astellas venture management home banner

Latest News

Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio

May 22, 2025

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies

Apr 09, 2025

Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize

Feb 27, 2025

About us

AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. For over 20 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster.

AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research.

Investment Scope

Investment Targets

We will make an investment in privately owned early-stage biotechnology company focused on therapeutics programs and platform technologies for drug discovery and development. Program stage should be in preclinical to be considered equity investment.

Areas of Interest

What AVM Provides

The strength of AVM lies in our “Pharma View” based on our long-standing experiences in the pharmaceutical industry. By providing our portfolio companies with invaluable information leveraging pharma expertise, we are able to support their growth. Moreover, we can be liaison between our portfolio companies and Astellas Pharma by helping them to facilitate a dialogue for future collaborations.

Contact

Astellas Venture Management LLC